AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol
This article was originally published in The Pink Sheet Daily
Executive Summary
A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.
You may also be interested in...
3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO
SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
Projected U.S. approval triggers Chinese NDA for the anemia drug.
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
Projected U.S. approval triggers Chinese NDA for the anemia drug.